6 results
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 in subjects with moderate to severe ulcerative colitis (UC).The secondary objectives are:-To…
To test the hypothesis that mirikizumab is superior to placebo in inducing clinical remission at Week 12 in patients with moderately to severely active ulcerative colitis (UC)
The purpose of the study is to investigate to what extent Exenatide MPF is tolerated.It will also be investigated how quickly and to what extent Exenatide, when administered as Exenatide MPF, is absorbed and eliminated from the body (this is called…
The primary objective of this pilot study is to determine the accuracy of measurement of the new Point of Care Test (POCT) glucose meter ACI3 from Roche Diagnostics on venous, arterial and capillary whole blood samples from adult hospital patients.…
The aim of this study is to determine the measurement accuracy of Roche Diagnostics' new Point of Care Test (POCT) glucose meter Cobas Pulse (formerly ACI3) on venous, arterial, and capillary whole blood samples from adult hospital patients…
To test the hypothesis that mirikizumab is superior to placebo in maintaining clinical remission at Week 40 (Week 52 of continuous therapy) among patients induced into clinical remission with mirikizumab